Antithrombotic Effects of Optimized Human Apyrase

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$790,435.00
Award Year:
2006
Program:
SBIR
Phase:
Phase II
Contract:
2R44HL076053-02
Agency Tracking Number:
HL076053
Solicitation Year:
2006
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2006-2
Small Business Information
APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC., 893 NORTH WARSON ROAD, SAINT LOUIS, MO, 63141
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
RIDONG CHEN
(314) 608-6932
RCHEN@NIDUSCENTER.COM
Business Contact:
RIDONG CHEN
(314) 812-8054
RCHEN@NIDUSCENTER.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The goal of the proposed work is to develop a novel antithrombotic drug that is safer and more effective than current therapies. Phase I funding for this project supported the successful development of a novel expression system to facilitate efficient production and purification of an optimized human apyrase as antithrombotic agent. Under Phase II support, we will extend the feasibility studies of Phase I to the development of a commercial Chinese hamster ovary cell line for high yield production. We will then utilize the recombinant protein to determine whether inhibition of platelet activation with the optimized apyrase in vivo attenuates thrombosis after arterial injury in rabbits and pigs. The ultimate goal of this research will be to develop APT102 as a frontline therapy for patients undergoing percutaneous coronary intervention as well as other patients with vascular disorders induced by excessive platelet activation.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government